Tourette Syndrome - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 55 pages report, published by Global Markets Direct

Keywords : Tourette Syndrome Therapeutic Products under Development, Key Players in Tourette Syndrome Therapeutics, Tourette Syndrome Pipeline Overview, Tourette Syndrome Pipeline, Tourette Syndrome Pipeline Assessment

Report ThumbnailSeptember-2013
Tourette Syndrome - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Tourette Syndrome - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tourette Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tourette Syndrome. Tourette Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Tourette Syndrome.
- A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Tourette Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Tourette Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Tourette Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Tourette Syndrome, H2 2013 7
  • Products under Development for Tourette Syndrome - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Route of Administration, H2 2013 24
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Molecule Type, H2 2013 26
  • Assessment by Stage and Molecule Type, H2 2013 27
  • List of Tables
  • Number of Products Under Development for Tourette Syndrome, H2 2013 7
  • Products under Development for Tourette Syndrome - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • AstraZeneca PLC, H2 2013 16
  • Neurocrine Biosciences, Inc., H2 2013 17
  • NeuroSearch A/S, H2 2013 18
  • Catalyst Pharmaceutical Partners, Inc., H2 2013 19
  • Auspex Pharmaceuticals, H2 2013 20
  • Reviva Pharmaceuticals Inc., H2 2013 21
  • Psyadon Pharmaceuticals, Inc., H2 2013 22
  • Assessment by Monotherapy Products, H2 2013 23
  • Assessment by Stage and Route of Administration, H2 2013 25
  • Assessment by Stage and Molecule Type, H2 2013 27
  • Tourette Syndrome Therapeutics - Drug Profile Updates 39
  • Tourette Syndrome Therapeutics - Discontinued Products 46
  • Tourette Syndrome Therapeutics - Dormant Products 47
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Tourette Syndrome Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Tourette Syndrome 7
  • Tourette Syndrome Therapeutics under Development by Companies 9
  • Tourette Syndrome Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Tourette Syndrome Therapeutics - Products under Development by Companies 14
  • Tourette Syndrome Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Tourette Syndrome Therapeutics Development 16
  • AstraZeneca PLC 16
  • Neurocrine Biosciences, Inc. 17
  • NeuroSearch A/S 18
  • Catalyst Pharmaceutical Partners, Inc. 19
  • Auspex Pharmaceuticals 20
  • Reviva Pharmaceuticals Inc. 21
  • Psyadon Pharmaceuticals, Inc. 22
  • Tourette Syndrome - Therapeutics Assessment 23
  • Assessment by Monotherapy Products 23
  • Assessment by Route of Administration 24
  • Assessment by Molecule Type 26
  • Drug Profiles 28
  • valbenazine - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • aripiprazole - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • seridopidine - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • ecopipam hydrochloride - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • AZD-5213 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • acetylcysteine - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • Tourette Syndrome Therapeutics - Drug Profile Updates 39
  • Tourette Syndrome Therapeutics - Discontinued Products 46
  • Tourette Syndrome Therapeutics - Dormant Products 47
  • Tourette Syndrome - Product Development Milestones 48
  • Featured News & Press Releases 48
  • Sep 24, 2012: Catalyst Pharma Announces Initiation Of CPP-109 Investigator-Sponsored Study In Patients With Treatment Refractory Tourette's Disorder 48
  • Jul 24, 2012: Psyadon Announces Positive Interim Analysis Of Phase II Study Of Ecopipam For Treatment Of Tourette Syndrome 48
  • Feb 09, 2012: Catalyst Files Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-115 In Treatment Of Tourette Syndrome 50
  • Feb 09, 2012: Catalyst Files US Provisional Patent Application For GABA Aminotransferase Inhibitor CPP-109 In Treatment Of Tourette Syndrome 50
  • Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854 50
  • May 11, 2011: Tourette Syndrome Association And Psyadon Pharma To Collaborate On Drug Trial For Tourette Syndrome Treatment 51
  • Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation 52
  • Nov 16, 2010: Otsuka Prevails In US Abilify Patent Litigation 52
  • Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial 52
  • Appendix 54
  • Methodology 54
  • Coverage 54
  • Secondary Research 54
  • Primary Research 54
  • Expert Panel Validation 54
  • Contact Us 55
  • Disclaimer 55

Please select a license type

Share

Related Products

Global Markets DirectTourette Syndrome - Pipeline Review, H2 2013Product ThumbnailTourette Syndrome - Pipeline Review, H2 2013, Industry ReportProduct #: 113335
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved